Prognostic significance of serum inflammation indices for different tumor infiltrative pattern types of gastric cancer

Figure 1 Representative hematoxylin and eosin staining patterns of samples of each tumor infiltrative pattern type. A: The expansive growth type; B: The intermediate type; C: The infiltrative growth type. INFa: The expansive growth type; INFb: The intermediate type; INFc: The infiltrative growth type.

Figure 2 Survival curve analyses for patients and receiver operating characteristic curves of inflammatory indices. A: Survival curves of all patients; B-D: Survival curves of patients with the expansive growth type (INFa), the intermediate type (INFb), and the infiltrative growth type (INFc); E-H: Receiver operating characteristic curve of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and systemic immune-inflammation index in all patients, INFa group, INFb group, and INFc group. INFa: The expansive growth type; INFb: The intermediate type; INFc: The infiltrative growth type; ROC: Receiver operating characteristic; NLR: Neutrophil-lymphocyte ratio; PLR: Platelet-lymphocyte ratio; SII: Systemic immune-inflammation index.

Figure 3 Survival curve analyses based on the systemic immune-inflammation index and platelet-lymphocyte ratio. A-D: Survival curves of patients with the expansive growth type based on the systemic immune-inflammation index in all stages, stage Ⅰ, stage Ⅱ, and stage Ⅲ; E–H: Survival curves of patients with the intermediate type based on the platelet-lymphocyte ratio (PLR) in all stages, stage Ⅰ, stage Ⅱ, and stage Ⅲ; I–L: Survival curves of patients with the infiltrative growth type based on the PLR in all stages, stage Ⅰ, stage Ⅱ, and stage Ⅲ. INFa: The expansive growth type; INFb: The intermediate type; INFc: The infiltrative growth type; PLR: Platelet-lymphocyte ratio; SII: Systemic immune-inflammation index.

Figure 4 Survival curve analyses based on postoperative chemotherapy. A-C: Survival curves with and without postoperative chemotherapy in all the expansive growth type (INFa) gastric cancer (GC) patients, INFa GC patients with systemic immune-inflammation index (SII) ≤ 523.01, and INFa GC patients with SII > 523.01; D-F: Survival curves with and without postoperative chemotherapy in all the intermediate type (INFb), GC patients, INFb GC patients with platelet-lymphocyte ratio (PLR) ≤ 134.02, and INFb GC patients with PLR > 134.02; G–I: Survival curves with and without postoperative chemotherapy in all the infiltrative growth type (INFc) GC patients, INFc GC patients with PLR ≤ 134.02, and INFc GC patients with PLR > 134.02. INFa: The expansive growth type; INFb: The intermediate type; INFc: The infiltrative growth type; PLR: Platelet-lymphocyte ratio; SII: Systemic immune-inflammation index.

Figure 5 The relationship between peripheral circulating immune cells and different tumor infiltrative pattern types. A-C: Boxplot combined with scatterplot of neutrophil percentage based on tumor infiltrative pattern (INF) types in stage Ⅰ, stage Ⅱ, and stage Ⅲ; D-F: Boxplot combined with scatterplot of lymphocyte percentage based on INF types in stage Ⅰ, stage Ⅱ, and stage Ⅲ; G–I: Boxplot combined with scatterplot of platelet count based on INF types in stage Ⅰ, stage Ⅱ, and stage Ⅲ. INFa: The expansive growth type; INFb: The intermediate type; INFc: The infiltrative growth type; PLT: Platelet.

Figure 6 Nomogram models predicting the survival of patients with different tumor infiltrative pattern types. A, D and G: Nomogram models predicting the 3-year and 5-year survival of patients with the expansive growth type (INFa), the intermediate type (INFb), and the infiltrative growth type (INFc) gastric cancer (GC); B and C: Receiver operating characteristic (ROC) of the nomogram model and postsurgical tumor node metastasis (pTNM) stage predicting the 3-year and 5-year survival of patients with INFa GC; E and F: ROC of the nomogram model and pTNM stage predicting the 3-year and 5-year survival of patients with INFb GC; H and I: ROC curve of the nomogram model and pTNM stage predicting the 3-year and 5-year survival of patients with INFc GC. INFa: The expansive growth type; INFb: The intermediate type; INFc: The infiltrative growth type; ROC: Receiver operating characteristic curve; mLNR: Metastatic lymph node ratio; BMI: Body mass index; PLR: Platelet-lymphocyte ratio; SII: Systemic immune-inflammation index.